nodes	percent_of_prediction	percent_of_DWPC	metapath
Pindolol—Transaminases increased—Carmustine—melanoma	0.012	0.024	CcSEcCtD
Pindolol—Isoprenaline—MAPK1—melanoma	0.0102	0.533	CrCbGaD
Pindolol—Aggression—Bleomycin—melanoma	0.00954	0.019	CcSEcCtD
Pindolol—Wheezing—Bleomycin—melanoma	0.00814	0.0162	CcSEcCtD
Pindolol—Heartburn—Docetaxel—melanoma	0.00683	0.0136	CcSEcCtD
Pindolol—Cardiac disorder—Vemurafenib—melanoma	0.00644	0.0129	CcSEcCtD
Pindolol—Angiopathy—Vemurafenib—melanoma	0.0063	0.0126	CcSEcCtD
Pindolol—Mediastinal disorder—Vemurafenib—melanoma	0.00626	0.0125	CcSEcCtD
Pindolol—Lethargy—Dactinomycin—melanoma	0.00579	0.0115	CcSEcCtD
Pindolol—Hot flush—Temozolomide—melanoma	0.00548	0.0109	CcSEcCtD
Pindolol—Menopausal symptoms—Temozolomide—melanoma	0.00544	0.0108	CcSEcCtD
Pindolol—Bronchospasm—Bleomycin—melanoma	0.00517	0.0103	CcSEcCtD
Pindolol—Myalgia—Vemurafenib—melanoma	0.00515	0.0103	CcSEcCtD
Pindolol—Arthralgia—Vemurafenib—melanoma	0.00515	0.0103	CcSEcCtD
Pindolol—Nervous system disorder—Vemurafenib—melanoma	0.00484	0.00965	CcSEcCtD
Pindolol—Hypotension—Vemurafenib—melanoma	0.00461	0.00919	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00449	0.00896	CcSEcCtD
Pindolol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00426	0.00849	CcSEcCtD
Pindolol—Fatigue—Vemurafenib—melanoma	0.00425	0.00848	CcSEcCtD
Pindolol—Constipation—Vemurafenib—melanoma	0.00422	0.00841	CcSEcCtD
Pindolol—Lightheadedness—Docetaxel—melanoma	0.00421	0.00838	CcSEcCtD
Pindolol—Pollakiuria—Temozolomide—melanoma	0.0041	0.00817	CcSEcCtD
Pindolol—Erectile dysfunction—Temozolomide—melanoma	0.00408	0.00814	CcSEcCtD
Pindolol—Depression—Carmustine—melanoma	0.00408	0.00813	CcSEcCtD
Pindolol—Weight increased—Temozolomide—melanoma	0.00404	0.00805	CcSEcCtD
Pindolol—Depression—Temozolomide—melanoma	0.00394	0.00786	CcSEcCtD
Pindolol—Cardiac failure congestive—Docetaxel—melanoma	0.00376	0.0075	CcSEcCtD
Pindolol—Hallucination—Carmustine—melanoma	0.00365	0.00729	CcSEcCtD
Pindolol—Hot flush—Docetaxel—melanoma	0.00365	0.00727	CcSEcCtD
Pindolol—Menopausal symptoms—Docetaxel—melanoma	0.00362	0.00721	CcSEcCtD
Pindolol—Visual disturbance—Docetaxel—melanoma	0.0036	0.00718	CcSEcCtD
Pindolol—Asthenia—Vemurafenib—melanoma	0.00354	0.00706	CcSEcCtD
Pindolol—Visual impairment—Carmustine—melanoma	0.00354	0.00706	CcSEcCtD
Pindolol—Hallucination—Temozolomide—melanoma	0.00353	0.00704	CcSEcCtD
Pindolol—Cardiac failure—Docetaxel—melanoma	0.0035	0.00697	CcSEcCtD
Pindolol—Pruritus—Vemurafenib—melanoma	0.00349	0.00696	CcSEcCtD
Pindolol—Lethargy—Docetaxel—melanoma	0.00348	0.00694	CcSEcCtD
Pindolol—Visual impairment—Temozolomide—melanoma	0.00342	0.00682	CcSEcCtD
Pindolol—Diarrhoea—Vemurafenib—melanoma	0.00338	0.00673	CcSEcCtD
Pindolol—Tinnitus—Temozolomide—melanoma	0.00331	0.0066	CcSEcCtD
Pindolol—Cardiac disorder—Temozolomide—melanoma	0.00329	0.00657	CcSEcCtD
Pindolol—Dizziness—Vemurafenib—melanoma	0.00326	0.00651	CcSEcCtD
Pindolol—Angiopathy—Temozolomide—melanoma	0.00322	0.00642	CcSEcCtD
Pindolol—Mental disorder—Carmustine—melanoma	0.00322	0.00642	CcSEcCtD
Pindolol—Mediastinal disorder—Temozolomide—melanoma	0.0032	0.00638	CcSEcCtD
Pindolol—Vomiting—Vemurafenib—melanoma	0.00314	0.00625	CcSEcCtD
Pindolol—Chest pain—Bleomycin—melanoma	0.00312	0.00622	CcSEcCtD
Pindolol—Myalgia—Bleomycin—melanoma	0.00312	0.00622	CcSEcCtD
Pindolol—Orthostatic hypotension—Docetaxel—melanoma	0.00312	0.00621	CcSEcCtD
Pindolol—Rash—Vemurafenib—melanoma	0.00311	0.0062	CcSEcCtD
Pindolol—Mental disorder—Temozolomide—melanoma	0.00311	0.0062	CcSEcCtD
Pindolol—Dermatitis—Vemurafenib—melanoma	0.00311	0.0062	CcSEcCtD
Pindolol—Headache—Vemurafenib—melanoma	0.00309	0.00616	CcSEcCtD
Pindolol—Cramp muscle—Docetaxel—melanoma	0.00307	0.00613	CcSEcCtD
Pindolol—Confusional state—Bleomycin—melanoma	0.00301	0.00601	CcSEcCtD
Pindolol—Tremor—Carmustine—melanoma	0.003	0.00597	CcSEcCtD
Pindolol—Oedema—Bleomycin—melanoma	0.00299	0.00596	CcSEcCtD
Pindolol—Nausea—Vemurafenib—melanoma	0.00293	0.00584	CcSEcCtD
Pindolol—Myalgia—Dactinomycin—melanoma	0.00291	0.0058	CcSEcCtD
Pindolol—Bronchospasm—Docetaxel—melanoma	0.0029	0.00578	CcSEcCtD
Pindolol—Tremor—Temozolomide—melanoma	0.00289	0.00577	CcSEcCtD
Pindolol—Hypotension—Bleomycin—melanoma	0.00279	0.00557	CcSEcCtD
Pindolol—Oedema—Dactinomycin—melanoma	0.00279	0.00556	CcSEcCtD
Pindolol—Vertigo—Temozolomide—melanoma	0.00278	0.00553	CcSEcCtD
Pindolol—Palpitations—Temozolomide—melanoma	0.00273	0.00544	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Bleomycin—melanoma	0.00272	0.00543	CcSEcCtD
Pindolol—Myalgia—Carmustine—melanoma	0.00272	0.00543	CcSEcCtD
Pindolol—Chest pain—Carmustine—melanoma	0.00272	0.00543	CcSEcCtD
Pindolol—Anxiety—Carmustine—melanoma	0.00271	0.00541	CcSEcCtD
Pindolol—Paraesthesia—Bleomycin—melanoma	0.00268	0.00535	CcSEcCtD
Pindolol—Weight increased—Docetaxel—melanoma	0.00268	0.00535	CcSEcCtD
Pindolol—Dyspnoea—Bleomycin—melanoma	0.00266	0.00531	CcSEcCtD
Pindolol—Confusional state—Carmustine—melanoma	0.00263	0.00525	CcSEcCtD
Pindolol—Myalgia—Temozolomide—melanoma	0.00263	0.00524	CcSEcCtD
Pindolol—Arthralgia—Temozolomide—melanoma	0.00263	0.00524	CcSEcCtD
Pindolol—Anxiety—Temozolomide—melanoma	0.00262	0.00523	CcSEcCtD
Pindolol—Oedema—Carmustine—melanoma	0.00261	0.0052	CcSEcCtD
Pindolol—Dry mouth—Temozolomide—melanoma	0.00257	0.00513	CcSEcCtD
Pindolol—Pain—Bleomycin—melanoma	0.00256	0.0051	CcSEcCtD
Pindolol—Conjunctivitis—Docetaxel—melanoma	0.00256	0.0051	CcSEcCtD
Pindolol—Tachycardia—Carmustine—melanoma	0.00255	0.00508	CcSEcCtD
Pindolol—Confusional state—Temozolomide—melanoma	0.00254	0.00507	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00254	0.00506	CcSEcCtD
Pindolol—Oedema—Temozolomide—melanoma	0.00252	0.00503	CcSEcCtD
Pindolol—Nervous system disorder—Temozolomide—melanoma	0.00247	0.00493	CcSEcCtD
Pindolol—Feeling abnormal—Bleomycin—melanoma	0.00246	0.00491	CcSEcCtD
Pindolol—Hypotension—Carmustine—melanoma	0.00244	0.00486	CcSEcCtD
Pindolol—Hyperhidrosis—Temozolomide—melanoma	0.00244	0.00486	CcSEcCtD
Pindolol—Nadolol—ABCB1—melanoma	0.00241	0.126	CrCbGaD
Pindolol—Fatigue—Dactinomycin—melanoma	0.0024	0.00479	CcSEcCtD
Pindolol—Pain—Dactinomycin—melanoma	0.00238	0.00475	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Carmustine—melanoma	0.00238	0.00474	CcSEcCtD
Pindolol—Insomnia—Carmustine—melanoma	0.00236	0.00471	CcSEcCtD
Pindolol—Paraesthesia—Carmustine—melanoma	0.00234	0.00467	CcSEcCtD
Pindolol—Dyspnoea—Carmustine—melanoma	0.00233	0.00464	CcSEcCtD
Pindolol—Somnolence—Carmustine—melanoma	0.00232	0.00463	CcSEcCtD
Pindolol—Feeling abnormal—Dactinomycin—melanoma	0.0023	0.00458	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Temozolomide—melanoma	0.0023	0.00458	CcSEcCtD
Pindolol—Insomnia—Temozolomide—melanoma	0.00228	0.00455	CcSEcCtD
Pindolol—Gastrointestinal pain—Dactinomycin—melanoma	0.00228	0.00455	CcSEcCtD
Pindolol—Visual impairment—Docetaxel—melanoma	0.00227	0.00454	CcSEcCtD
Pindolol—Paraesthesia—Temozolomide—melanoma	0.00226	0.00451	CcSEcCtD
Pindolol—Gastrointestinal disorder—Carmustine—melanoma	0.00225	0.00449	CcSEcCtD
Pindolol—Dyspnoea—Temozolomide—melanoma	0.00225	0.00448	CcSEcCtD
Pindolol—Somnolence—Temozolomide—melanoma	0.00224	0.00447	CcSEcCtD
Pindolol—Constipation—Carmustine—melanoma	0.00223	0.00445	CcSEcCtD
Pindolol—Pain—Carmustine—melanoma	0.00223	0.00445	CcSEcCtD
Pindolol—Dyspepsia—Temozolomide—melanoma	0.00222	0.00443	CcSEcCtD
Pindolol—Abdominal pain—Dactinomycin—melanoma	0.0022	0.00439	CcSEcCtD
Pindolol—Cardiac disorder—Docetaxel—melanoma	0.00219	0.00437	CcSEcCtD
Pindolol—Gastrointestinal disorder—Temozolomide—melanoma	0.00218	0.00434	CcSEcCtD
Pindolol—Fatigue—Temozolomide—melanoma	0.00217	0.00433	CcSEcCtD
Pindolol—Pain—Temozolomide—melanoma	0.00216	0.0043	CcSEcCtD
Pindolol—Constipation—Temozolomide—melanoma	0.00216	0.0043	CcSEcCtD
Pindolol—Feeling abnormal—Carmustine—melanoma	0.00215	0.00429	CcSEcCtD
Pindolol—Asthenia—Bleomycin—melanoma	0.00214	0.00428	CcSEcCtD
Pindolol—Angiopathy—Docetaxel—melanoma	0.00214	0.00427	CcSEcCtD
Pindolol—Gastrointestinal pain—Carmustine—melanoma	0.00213	0.00425	CcSEcCtD
Pindolol—Mediastinal disorder—Docetaxel—melanoma	0.00213	0.00424	CcSEcCtD
Pindolol—Pruritus—Bleomycin—melanoma	0.00211	0.00422	CcSEcCtD
Pindolol—Atenolol—ABCB1—melanoma	0.0021	0.11	CrCbGaD
Pindolol—Feeling abnormal—Temozolomide—melanoma	0.00208	0.00414	CcSEcCtD
Pindolol—Mental disorder—Docetaxel—melanoma	0.00207	0.00412	CcSEcCtD
Pindolol—Abdominal pain—Carmustine—melanoma	0.00206	0.00411	CcSEcCtD
Pindolol—Gastrointestinal pain—Temozolomide—melanoma	0.00206	0.00411	CcSEcCtD
Pindolol—Asthenia—Dactinomycin—melanoma	0.002	0.00399	CcSEcCtD
Pindolol—Abdominal pain—Temozolomide—melanoma	0.00199	0.00397	CcSEcCtD
Pindolol—Muscle spasms—Docetaxel—melanoma	0.00198	0.00394	CcSEcCtD
Pindolol—Acebutolol—ABCB1—melanoma	0.00194	0.102	CrCbGaD
Pindolol—Diarrhoea—Dactinomycin—melanoma	0.00191	0.0038	CcSEcCtD
Pindolol—Vomiting—Bleomycin—melanoma	0.0019	0.00379	CcSEcCtD
Pindolol—Rash—Bleomycin—melanoma	0.00188	0.00376	CcSEcCtD
Pindolol—Dermatitis—Bleomycin—melanoma	0.00188	0.00375	CcSEcCtD
Pindolol—Asthenia—Carmustine—melanoma	0.00187	0.00373	CcSEcCtD
Pindolol—Syncope—Docetaxel—melanoma	0.00184	0.00367	CcSEcCtD
Pindolol—Palpitations—Docetaxel—melanoma	0.00182	0.00362	CcSEcCtD
Pindolol—Asthenia—Temozolomide—melanoma	0.00181	0.00361	CcSEcCtD
Pindolol—Loss of consciousness—Docetaxel—melanoma	0.00181	0.0036	CcSEcCtD
Pindolol—Diarrhoea—Carmustine—melanoma	0.00179	0.00356	CcSEcCtD
Pindolol—Pruritus—Temozolomide—melanoma	0.00178	0.00356	CcSEcCtD
Pindolol—Nausea—Bleomycin—melanoma	0.00178	0.00354	CcSEcCtD
Pindolol—Vomiting—Dactinomycin—melanoma	0.00177	0.00353	CcSEcCtD
Pindolol—Rash—Dactinomycin—melanoma	0.00176	0.0035	CcSEcCtD
Pindolol—Chest pain—Docetaxel—melanoma	0.00175	0.00349	CcSEcCtD
Pindolol—Myalgia—Docetaxel—melanoma	0.00175	0.00349	CcSEcCtD
Pindolol—Arthralgia—Docetaxel—melanoma	0.00175	0.00349	CcSEcCtD
Pindolol—Dizziness—Carmustine—melanoma	0.00173	0.00344	CcSEcCtD
Pindolol—Diarrhoea—Temozolomide—melanoma	0.00173	0.00344	CcSEcCtD
Pindolol—Dry mouth—Docetaxel—melanoma	0.00171	0.00341	CcSEcCtD
Pindolol—Confusional state—Docetaxel—melanoma	0.00169	0.00337	CcSEcCtD
Pindolol—Oedema—Docetaxel—melanoma	0.00168	0.00334	CcSEcCtD
Pindolol—Dizziness—Temozolomide—melanoma	0.00167	0.00332	CcSEcCtD
Pindolol—Vomiting—Carmustine—melanoma	0.00166	0.00331	CcSEcCtD
Pindolol—Nausea—Dactinomycin—melanoma	0.00166	0.0033	CcSEcCtD
Pindolol—Shock—Docetaxel—melanoma	0.00165	0.00329	CcSEcCtD
Pindolol—Rash—Carmustine—melanoma	0.00165	0.00328	CcSEcCtD
Pindolol—Nervous system disorder—Docetaxel—melanoma	0.00164	0.00328	CcSEcCtD
Pindolol—Dermatitis—Carmustine—melanoma	0.00164	0.00328	CcSEcCtD
Pindolol—Metoprolol—ABCB1—melanoma	0.00164	0.0858	CrCbGaD
Pindolol—Tachycardia—Docetaxel—melanoma	0.00164	0.00326	CcSEcCtD
Pindolol—Headache—Carmustine—melanoma	0.00163	0.00326	CcSEcCtD
Pindolol—Vomiting—Temozolomide—melanoma	0.0016	0.0032	CcSEcCtD
Pindolol—Rash—Temozolomide—melanoma	0.00159	0.00317	CcSEcCtD
Pindolol—Dermatitis—Temozolomide—melanoma	0.00159	0.00317	CcSEcCtD
Pindolol—Headache—Temozolomide—melanoma	0.00158	0.00315	CcSEcCtD
Pindolol—Hypotension—Docetaxel—melanoma	0.00157	0.00312	CcSEcCtD
Pindolol—Nausea—Carmustine—melanoma	0.00155	0.00309	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Docetaxel—melanoma	0.00153	0.00305	CcSEcCtD
Pindolol—Insomnia—Docetaxel—melanoma	0.00152	0.00302	CcSEcCtD
Pindolol—Paraesthesia—Docetaxel—melanoma	0.00151	0.003	CcSEcCtD
Pindolol—Nausea—Temozolomide—melanoma	0.0015	0.00299	CcSEcCtD
Pindolol—Dyspnoea—Docetaxel—melanoma	0.00149	0.00298	CcSEcCtD
Pindolol—Somnolence—Docetaxel—melanoma	0.00149	0.00297	CcSEcCtD
Pindolol—Dyspepsia—Docetaxel—melanoma	0.00148	0.00294	CcSEcCtD
Pindolol—Gastrointestinal disorder—Docetaxel—melanoma	0.00145	0.00289	CcSEcCtD
Pindolol—Fatigue—Docetaxel—melanoma	0.00145	0.00288	CcSEcCtD
Pindolol—Constipation—Docetaxel—melanoma	0.00143	0.00286	CcSEcCtD
Pindolol—Pain—Docetaxel—melanoma	0.00143	0.00286	CcSEcCtD
Pindolol—Feeling abnormal—Docetaxel—melanoma	0.00138	0.00276	CcSEcCtD
Pindolol—Gastrointestinal pain—Docetaxel—melanoma	0.00137	0.00273	CcSEcCtD
Pindolol—Abdominal pain—Docetaxel—melanoma	0.00133	0.00264	CcSEcCtD
Pindolol—Asthenia—Docetaxel—melanoma	0.0012	0.0024	CcSEcCtD
Pindolol—Pruritus—Docetaxel—melanoma	0.00119	0.00237	CcSEcCtD
Pindolol—Diarrhoea—Docetaxel—melanoma	0.00115	0.00229	CcSEcCtD
Pindolol—Dizziness—Docetaxel—melanoma	0.00111	0.00221	CcSEcCtD
Pindolol—Vomiting—Docetaxel—melanoma	0.00107	0.00213	CcSEcCtD
Pindolol—Rash—Docetaxel—melanoma	0.00106	0.00211	CcSEcCtD
Pindolol—Dermatitis—Docetaxel—melanoma	0.00106	0.00211	CcSEcCtD
Pindolol—Headache—Docetaxel—melanoma	0.00105	0.00209	CcSEcCtD
Pindolol—Nausea—Docetaxel—melanoma	0.000996	0.00199	CcSEcCtD
Pindolol—Propranolol—ABCB1—melanoma	0.000827	0.0433	CrCbGaD
Pindolol—ADRB3—Signaling Pathways—CDKN1B—melanoma	8.6e-05	0.000179	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—MAPK3—melanoma	8.54e-05	0.000178	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—AKT1—melanoma	8.51e-05	0.000178	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—SPP1—melanoma	8.5e-05	0.000177	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—MAP2K2—melanoma	8.48e-05	0.000177	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CXCL8—melanoma	8.47e-05	0.000177	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—IL2—melanoma	8.46e-05	0.000176	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CASP3—melanoma	8.43e-05	0.000176	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—TERT—melanoma	8.43e-05	0.000176	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—IL2—melanoma	8.42e-05	0.000176	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—RAC1—melanoma	8.4e-05	0.000175	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—BRAF—melanoma	8.38e-05	0.000175	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—IL6—melanoma	8.38e-05	0.000175	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—CYP17A1—melanoma	8.33e-05	0.000174	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—IL2—melanoma	8.27e-05	0.000173	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—TERT—melanoma	8.24e-05	0.000172	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—RAC1—melanoma	8.22e-05	0.000171	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCND1—melanoma	8.21e-05	0.000171	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—IGF1—melanoma	8.16e-05	0.00017	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CTNNB1—melanoma	8.13e-05	0.00017	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—MAPK1—melanoma	8.12e-05	0.000169	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—EGFR—melanoma	8.12e-05	0.000169	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—IL2—melanoma	8.09e-05	0.000169	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—TERT—melanoma	8.06e-05	0.000168	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—HIF1A—melanoma	8.06e-05	0.000168	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—RAC1—melanoma	8.04e-05	0.000168	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—MMP9—melanoma	7.97e-05	0.000166	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CDKN1A—melanoma	7.94e-05	0.000166	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—PTEN—melanoma	7.92e-05	0.000165	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—MAP2K1—melanoma	7.89e-05	0.000165	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—HIF1A—melanoma	7.88e-05	0.000164	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—NFKB1—melanoma	7.88e-05	0.000164	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—GNA11—melanoma	7.86e-05	0.000164	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—PIK3CD—melanoma	7.84e-05	0.000163	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—PIK3CA—melanoma	7.76e-05	0.000162	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—AKT1—melanoma	7.73e-05	0.000161	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—HIF1A—melanoma	7.71e-05	0.000161	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—KDR—melanoma	7.71e-05	0.000161	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—FASN—melanoma	7.69e-05	0.000161	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—KRAS—melanoma	7.67e-05	0.00016	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—SLC5A5—melanoma	7.57e-05	0.000158	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—KDR—melanoma	7.54e-05	0.000157	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—FGF2—melanoma	7.5e-05	0.000157	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—FN1—melanoma	7.42e-05	0.000155	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—KDR—melanoma	7.37e-05	0.000154	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—CD44—melanoma	7.31e-05	0.000152	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—GNAQ—melanoma	7.31e-05	0.000152	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—NOTCH1—melanoma	7.26e-05	0.000151	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—FN1—melanoma	7.26e-05	0.000151	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—VEGFA—melanoma	7.15e-05	0.000149	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CD80—melanoma	7.11e-05	0.000148	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—NOTCH1—melanoma	7.1e-05	0.000148	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—KIT—melanoma	7.1e-05	0.000148	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—APC—melanoma	7.1e-05	0.000148	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—PIK3CG—melanoma	7.1e-05	0.000148	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—NRAS—melanoma	7.1e-05	0.000148	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—FN1—melanoma	7.1e-05	0.000148	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—STAT3—melanoma	7.08e-05	0.000148	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—NRAS—melanoma	7.07e-05	0.000147	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—PIK3CA—melanoma	7.05e-05	0.000147	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—MDM2—melanoma	7.02e-05	0.000146	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—EGF—melanoma	7.02e-05	0.000146	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—CYP1B1—melanoma	7.01e-05	0.000146	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CD80—melanoma	6.96e-05	0.000145	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—APC—melanoma	6.95e-05	0.000145	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—PIK3CG—melanoma	6.95e-05	0.000145	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—KIT—melanoma	6.95e-05	0.000145	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—NRAS—melanoma	6.95e-05	0.000145	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—NOTCH1—melanoma	6.95e-05	0.000145	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—ERBB2—melanoma	6.92e-05	0.000144	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—EGF—melanoma	6.87e-05	0.000143	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—PIK3CB—melanoma	6.83e-05	0.000143	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CD80—melanoma	6.8e-05	0.000142	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—MAPK3—melanoma	6.8e-05	0.000142	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—APC—melanoma	6.79e-05	0.000142	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—PIK3CG—melanoma	6.79e-05	0.000142	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—KIT—melanoma	6.79e-05	0.000142	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—NRAS—melanoma	6.79e-05	0.000142	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—MAPK3—melanoma	6.77e-05	0.000141	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—EGF—melanoma	6.71e-05	0.00014	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—BRAF—melanoma	6.67e-05	0.000139	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—MAPK3—melanoma	6.65e-05	0.000139	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—MYC—melanoma	6.58e-05	0.000137	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CXCL8—melanoma	6.57e-05	0.000137	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—BRAF—melanoma	6.53e-05	0.000136	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—HRAS—melanoma	6.52e-05	0.000136	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—MAPK3—melanoma	6.5e-05	0.000136	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—IGF1—melanoma	6.5e-05	0.000136	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—MAPK1—melanoma	6.47e-05	0.000135	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—EGFR—melanoma	6.47e-05	0.000135	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—MAPK1—melanoma	6.44e-05	0.000134	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—EGFR—melanoma	6.44e-05	0.000134	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CDKN1B—melanoma	6.41e-05	0.000134	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—BRAF—melanoma	6.38e-05	0.000133	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—IGF1—melanoma	6.36e-05	0.000133	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—AKT1—melanoma	6.34e-05	0.000132	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—MAPK1—melanoma	6.33e-05	0.000132	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—EGFR—melanoma	6.33e-05	0.000132	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CASP3—melanoma	6.28e-05	0.000131	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—MAP2K1—melanoma	6.28e-05	0.000131	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—IL2—melanoma	6.27e-05	0.000131	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—IL6—melanoma	6.24e-05	0.00013	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—PIK3CD—melanoma	6.24e-05	0.00013	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—IGF1—melanoma	6.22e-05	0.00013	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—MAPK1—melanoma	6.19e-05	0.000129	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—EGFR—melanoma	6.19e-05	0.000129	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	6.18e-05	0.000129	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—MAP2K1—melanoma	6.15e-05	0.000128	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCND1—melanoma	6.12e-05	0.000128	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—KRAS—melanoma	6.11e-05	0.000127	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—PIK3CD—melanoma	6.11e-05	0.000127	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—KRAS—melanoma	6.08e-05	0.000127	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CTNNB1—melanoma	6.06e-05	0.000126	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	6.05e-05	0.000126	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—MAP2K1—melanoma	6.01e-05	0.000125	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—KRAS—melanoma	5.98e-05	0.000125	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—FGF2—melanoma	5.98e-05	0.000125	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—PIK3CD—melanoma	5.97e-05	0.000125	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—MMP9—melanoma	5.94e-05	0.000124	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CDKN1A—melanoma	5.92e-05	0.000123	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	5.91e-05	0.000123	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—PTEN—melanoma	5.9e-05	0.000123	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—NFKB1—melanoma	5.88e-05	0.000123	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—FGF2—melanoma	5.85e-05	0.000122	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—KRAS—melanoma	5.85e-05	0.000122	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—ABCB1—melanoma	5.77e-05	0.00012	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—AKT1—melanoma	5.76e-05	0.00012	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—FGF2—melanoma	5.72e-05	0.000119	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	5.61e-05	0.000117	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—MDM2—melanoma	5.59e-05	0.000117	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—PIK3CA—melanoma	5.59e-05	0.000117	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—ERBB2—melanoma	5.51e-05	0.000115	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	5.49e-05	0.000115	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—MDM2—melanoma	5.47e-05	0.000114	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—PIK3CB—melanoma	5.44e-05	0.000113	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—TP53—melanoma	5.41e-05	0.000113	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—ERBB2—melanoma	5.39e-05	0.000113	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—PIK3CA—melanoma	5.37e-05	0.000112	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—MDM2—melanoma	5.35e-05	0.000112	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—VEGFA—melanoma	5.33e-05	0.000111	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—PIK3CB—melanoma	5.32e-05	0.000111	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PRKCA—melanoma	5.31e-05	0.000111	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—STAT3—melanoma	5.28e-05	0.00011	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—ERBB2—melanoma	5.27e-05	0.00011	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—ERCC2—melanoma	5.27e-05	0.00011	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—NRAS—melanoma	5.27e-05	0.00011	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CXCL8—melanoma	5.23e-05	0.000109	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—PIK3CB—melanoma	5.2e-05	0.000109	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—HRAS—melanoma	5.19e-05	0.000108	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—HRAS—melanoma	5.17e-05	0.000108	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CXCL8—melanoma	5.11e-05	0.000107	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CDKN1B—melanoma	5.11e-05	0.000107	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—HRAS—melanoma	5.08e-05	0.000106	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—AKT1—melanoma	5.05e-05	0.000105	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—MAPK3—melanoma	5.04e-05	0.000105	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CASP3—melanoma	5e-05	0.000104	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CXCL8—melanoma	5e-05	0.000104	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—IL2—melanoma	5e-05	0.000104	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CDKN1B—melanoma	4.99e-05	0.000104	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—IL6—melanoma	4.97e-05	0.000104	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—HRAS—melanoma	4.97e-05	0.000104	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—IL6—melanoma	4.95e-05	0.000103	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—AKT1—melanoma	4.94e-05	0.000103	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—MYC—melanoma	4.91e-05	0.000102	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CASP3—melanoma	4.9e-05	0.000102	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—IL2—melanoma	4.89e-05	0.000102	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CDKN1B—melanoma	4.88e-05	0.000102	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCND1—melanoma	4.87e-05	0.000102	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—IL6—melanoma	4.86e-05	0.000101	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—AKT1—melanoma	4.83e-05	0.000101	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CTNNB1—melanoma	4.82e-05	0.000101	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—MAPK1—melanoma	4.8e-05	0.0001	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—EGFR—melanoma	4.8e-05	0.0001	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CASP3—melanoma	4.79e-05	9.98e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—IL2—melanoma	4.78e-05	9.97e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCND1—melanoma	4.76e-05	9.94e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—IL6—melanoma	4.76e-05	9.92e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—MMP9—melanoma	4.73e-05	9.86e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CTNNB1—melanoma	4.72e-05	9.84e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CDKN1A—melanoma	4.71e-05	9.83e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—PTEN—melanoma	4.7e-05	9.81e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—NFKB1—melanoma	4.68e-05	9.76e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCND1—melanoma	4.66e-05	9.72e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—MMP9—melanoma	4.63e-05	9.65e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CTNNB1—melanoma	4.61e-05	9.62e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CDKN1A—melanoma	4.61e-05	9.62e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—PTEN—melanoma	4.6e-05	9.59e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—AKT1—melanoma	4.59e-05	9.57e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—NFKB1—melanoma	4.58e-05	9.55e-05	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—AKT1—melanoma	4.57e-05	9.52e-05	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—KRAS—melanoma	4.53e-05	9.46e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—MMP9—melanoma	4.52e-05	9.44e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CDKN1A—melanoma	4.51e-05	9.4e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—PTEN—melanoma	4.5e-05	9.38e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—AKT1—melanoma	4.49e-05	9.36e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—NFKB1—melanoma	4.48e-05	9.34e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—AKT1—melanoma	4.39e-05	9.15e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—VEGFA—melanoma	4.25e-05	8.86e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—STAT3—melanoma	4.2e-05	8.77e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—NRAS—melanoma	4.19e-05	8.75e-05	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—PIK3CA—melanoma	4.16e-05	8.69e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PIK3CG—melanoma	4.16e-05	8.68e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—VEGFA—melanoma	4.15e-05	8.67e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—STAT3—melanoma	4.11e-05	8.58e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—NRAS—melanoma	4.1e-05	8.56e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—VEGFA—melanoma	4.06e-05	8.47e-05	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—TP53—melanoma	4.03e-05	8.4e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—STAT3—melanoma	4.02e-05	8.39e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—MAPK3—melanoma	4.02e-05	8.38e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PPARG—melanoma	4.01e-05	8.38e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—NRAS—melanoma	4.01e-05	8.37e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—MAPK3—melanoma	3.93e-05	8.2e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—MYC—melanoma	3.91e-05	8.15e-05	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—HRAS—melanoma	3.85e-05	8.04e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—MAPK3—melanoma	3.84e-05	8.02e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—MAPK1—melanoma	3.82e-05	7.97e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—MYC—melanoma	3.82e-05	7.97e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—EGFR—melanoma	3.82e-05	7.97e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—MAPK1—melanoma	3.74e-05	7.8e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—EGFR—melanoma	3.74e-05	7.8e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—MYC—melanoma	3.74e-05	7.8e-05	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—IL6—melanoma	3.69e-05	7.69e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PIK3CD—melanoma	3.66e-05	7.63e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—MAPK1—melanoma	3.66e-05	7.63e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—EGFR—melanoma	3.66e-05	7.63e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—KRAS—melanoma	3.61e-05	7.53e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—ALB—melanoma	3.61e-05	7.53e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—KRAS—melanoma	3.53e-05	7.37e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—KRAS—melanoma	3.45e-05	7.2e-05	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—AKT1—melanoma	3.4e-05	7.1e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—PIK3CA—melanoma	3.32e-05	6.92e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—PIK3CA—melanoma	3.24e-05	6.77e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—TP53—melanoma	3.21e-05	6.69e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PIK3CB—melanoma	3.19e-05	6.65e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—PIK3CA—melanoma	3.17e-05	6.62e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PTGS2—melanoma	3.16e-05	6.59e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—TP53—melanoma	3.14e-05	6.55e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—TP53—melanoma	3.07e-05	6.4e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—HRAS—melanoma	3.07e-05	6.4e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—HRAS—melanoma	3e-05	6.26e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—IL6—melanoma	2.94e-05	6.13e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—HRAS—melanoma	2.94e-05	6.12e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—IL6—melanoma	2.87e-05	5.99e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—IL6—melanoma	2.81e-05	5.86e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PTEN—melanoma	2.75e-05	5.75e-05	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—AKT1—melanoma	2.71e-05	5.65e-05	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—AKT1—melanoma	2.65e-05	5.53e-05	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—AKT1—melanoma	2.59e-05	5.41e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—PIK3CA—melanoma	1.94e-05	4.05e-05	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—AKT1—melanoma	1.59e-05	3.31e-05	CbGpPWpGaD
